Name: KLRC1 (HY-0102 Biosimilar) Recombinant Monoclonal Antibody
Brand: CUSABIO
SKU: CSB-RA012466MB1HU

Product Details

Uniprot No.

P26715

Target Names

KLRC1

Alternative Names

HY000102 research-grade biosimilar; HY 0102 research-grade biosimilar; HY-0102 research-grade biosimilar ;KLRC1 antibody; NKG2A antibody; NKG2-A/NKG2-B type II integral membrane protein antibody; CD159 antigen-like family member A antibody; NK cell receptor A antibody; NKG2-A/B-activating NK receptor antibody; CD antigen CD159a antibody

Species Reactivity

Human

Immunogen

Recombinant Human KLRC1 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

0.01M PBS，pH7.4

Form

Liquid

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

3-4 weeks

Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to reference antibody HY-0102, targeting KLRC1 (Killer cell lectin-like receptor subfamily C member 1), also known as NKG2A. KLRC1 is an inhibitory receptor predominantly expressed on natural killer (NK) cells and subsets of CD8+ T cells, where it forms a heterodimer with CD94. Upon binding to its ligand HLA-E, KLRC1/CD94 delivers inhibitory signals that suppress NK cell-mediated cytotoxicity and T cell activation, serving as a critical immune checkpoint. This receptor plays significant roles in immune tolerance, viral immune evasion, and tumor escape mechanisms, making it relevant to cancer immunology, transplantation research, and viral pathogenesis studies.

As a biosimilar to HY-0102, this antibody provides researchers with a validated tool for investigating KLRC1-mediated immune regulation and checkpoint inhibition pathways. It supports studies examining NK cell function, tumor immunosuppression mechanisms, and the therapeutic potential of blocking KLRC1/HLA-E interactions to enhance anti-tumor immunity. This antibody is valuable for immunology research, oncology studies, and the development of novel immunotherapeutic strategies.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Related Products

Target Background

Function

Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self. Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules. Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions. Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity. On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFB1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens. In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion.; (Microbial infection) Viruses like human cytomegalovirus have evolved an escape mechanism whereby virus-induced down-regulation of host MHC class I molecules is coupled to the binding of viral peptides to HLA-E, restoring HLA-E expression and inducing HLA-E-dependent NK cell immune tolerance to infected cells. Recognizes HLA-E in complex with human cytomegalovirus UL40-derived peptide (VMAPRTLIL) and inhibits NK cell cytotoxicity.; (Microbial infection) May recognize HLA-E in complex with HIV-1 gag/Capsid protein p24-derived peptide (AISPRTLNA) on infected cells and may inhibit NK cell cytotoxicity, a mechanism that allows HIV-1 to escape immune recognition.; (Microbial infection) Upon SARS-CoV-2 infection, may contribute to functional exhaustion of cytotoxic NK cells and CD8-positive T cells. On NK cells, may recognize HLA-E in complex with SARS-CoV-2 S/Spike protein S1-derived peptide (LQPRTFLL) expressed on the surface of lung epithelial cells, inducing NK cell exhaustion and dampening antiviral immune surveillance.

Gene References into Functions

Compared with NKG2D, NKG2A expressed on both peripheral CD3-CD56+NK cells and CD3+CD8+T cells plays a more pivotal negative regulatory role in the progression of HBV-related ACLF. PMID: 27828717
These results indicate NKG2A inhibitory receptor may play a key role in transfusion-induced immunodepression of NK cells in patients with b-thalassemia major PMID: 27465324
Collectively, these results provide evidence for the first time that CD94/NKG2C is involved in chronic graft-versus-host disease prevention PMID: 27801784
CD94 and NKG2A polymorphisms may contribute to genetic susceptibility to rheumatoid arthritis or affect the response to anti-TNF therapy in patients of Caucasian origin. PMID: 26453102
NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation. PMID: 26856773
The presence of TIM3+and/or NKG2A+ T cells is associated with the absence of recurrences and a longer recurrence-free survival. PMID: 25220367
Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. PMID: 24673109
Results suggested that the low expression level of CD94/NKG2A upon gammadelta T cell activation might lead to the over-activation of gammadelta T cells in patients with SLE. PMID: 22486170
The positive expression rate of NKG2D and NKG2A on NK cells and CD3(+) T cells in ALL patients was no significantly different from that in AML patients. PMID: 21518478
The level of NKG2A expression on resting CD8-positive T cells inversely correlated with acquisition of regulatory function when activated. PMID: 21538351
These results suggested that these glycans can interact with NKG2D and CD94 to modulate NK cell-dependent cytotoxicity. PMID: 21212510
The differences of CD94 and NKG2 expression between nasal NK/T-cell lymphomas and B cell lymphoma or T cell lymphoma were statistically significant. PMID: 20654155
NKG2A expression on gammadelta lymphoproliferative Disease of Large Granular Lymphocytes correlates with asymptomatic pathology, even in the presence of NKG2C coexpression. PMID: 20952657
CD56(dim) NK cells continue to differentiate. During this process, they lose expression of NKG2A, sequentially acquire inhibitory killer cell inhibitory immunoglobulin-like receptors and CD57. PMID: 20696944
a new model in which the NK cell differentiation and functional fate are based on a stepwise decrease of NKG2A and acquisition of KIRs PMID: 20700504
NK cell NKG2A expression is dysregulated in chronic hepatitis C. NKG2A-positive NK cells are associated with a beneficial response to pegylated interferon and ribavirin therapy. PMID: 20550548
Results sugges that KLRC1 can be a probable candidate gene for SLE on 12p12.3-13.2, but which is not associated with the disease activity. PMID: 17545086
alloreactivity of a significant fraction of KIR(-) NK cells leads to killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts that is mediated by NKG2A and LIR-1. PMID: 20139023
negatively controls decidual NK cell cytotoxicity PMID: 19615756
expression by Vdelta2+ T cells is higher in pregnant women PMID: 19395088
increased CD8+ T-cell subsets as well as the abnormal expression of NKG2A and NKG2D on CD3+ T and CD3-CD56 + NK cells may play a role in the etiology of systemic lupus erythematosus PMID: 20012119
demonstrate that human cytomegalovirus induces an immediate proportional enlargement of a functionally active CD94/NKG2A expressing subset of natural killer cells. PMID: 19782712
Role that each NKG2A immunoreceptor tyrosine-based inhibitory motif plays in mediating the human CD94/NKG2A inhibitory signal. PMID: 12165520
TCR antigenic specificity dictates NKG2A commitment, which critically regulates subsequent activation of CTL. PMID: 12387742
NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes. PMID: 12444112
CD94/NKG2A+ NK cells can recognize stressed cells in a peptide-dependent manner. PMID: 12461076
Aberrant expression of natural killer (NK) receptors NKG2A/CD94 may have an impact on the magnitude and direction of dendritic cell activation of T cells under pathological conditions, such as chronic hepatitis C virus infection. PMID: 15528343
reveal strict gene regulatory mechanisms for CD94 and NKG2 gene expression on CD4+ cells PMID: 15550116
Expression of the inhibitory NKR (CD94/NKG2A) of the G-CSF mobilized peripheral blood mononuclear cells. PMID: 15561299
immaturity of NK cells and inhibitory effect of NKG2A override graft versus leukemia effect PMID: 15687235
only a subpopulation of NK cells expressing high levels of the inhibitory receptor NKG2A are able to lyse autologous vaccinia-infected targets, and that this is due to selective down-regulation of HLA-E PMID: 16434388
identified co-induction of NKG2A and CD56 on activation of TH2 cells PMID: 16690409
Prevents actin-dependent recruitment of raft-associated activation receptors complexes to the activating immunologic synapse. PMID: 16951318
Increased expression of CD94/NKG2A in peritoneal NK cells may mediate the resistance of endometriotic tissue to NK cell-mediated lysis, thus contributing to the progression of the disease. PMID: 17706207
indicate that the SNPs of the inhibitory receptor CD94/NKG2A and its haplotypes, as well as its ligand HLA-E, are associated with Behcet's disease immune systems PMID: 17767552
We show that signalling through NKG2A suppresses TH2 effector function. This may provide a means to modulate Th1/Th2 balance in diseases where Th2 cytokines predominate. PMID: 17927829
The results indicated that the high expression of NKG2A/CD94 and low expression of granzyme B may be related with the reduced activity of cord blood NK cells. PMID: 17976318
High levels of NKG2A is associated with tongue cancer PMID: 18056444
the invariant CD94 chain plays a more dominant role in interacting with HLA-E in comparison to the variable NKG2 chain. PMID: 18083576
HIV-1 infection is associated with higher levels NKG2A in the cytotoxic NK subset in HIV-1-infected patients with more advanced disease. PMID: 18172398
crystal structure of CD94-NKG2A in complex with HLA-E bound to a peptide derived from the leader sequence of HLA-G PMID: 18332182
The evolution of the NKG2x/CD94 family of receptors has likely been shaped both by the need to bind the invariant HLA-E ligand and the need to avoid subversion by pathogen-derived decoys. PMID: 18448674
T cells were highly susceptible to NKG2A-mediated inhibition of cytotoxic activity and NKG2A(+) lymphocytes were preferentially attracted by CCR5 ligands induced by hepatitis C virus E2 antigen. PMID: 18500933
No significance was observed between the inhibitory (NKG2A) or activating (NKG2C and NKG2D) receptor genotypes and the presence of RF, ANA, or bony erosions in Rheumatoid arthritis. PMID: 18700876
NKG2A expression is inversely correlated with the number of coexpressed killer inhibitory receptors (KIR) and is more frequent on KIR3DL2-single positive natural killer cells. PMID: 18941190
MICA-NKG2D interaction constitutes a mechanism by which monocytes and NK cells as an early source of IFN-gamma may communicate directly during an innate immune response to infections in humans. PMID: 18981088
Data suggest that RNAi-mediated silencing of NKG2A in effector cells could improve the efficacy of cell-based immunotherapies but also show that indirect effects of NKG2A knockdown exist. PMID: 19002424
Under the influence of interleukin-12 stimulation, CD94/NKG2A is transiently inducible in natural killer (NK) cells bearing the homologous CD94/NKG2C-activating receptor,providing a potential negative regulatory feedback mechanism. PMID: 19124726
Although the percentages of both NKG2A- and NKG2C-positive NK cells were normal in preeclamptic women, the levels of NKG2A and NKG2C on NK cells were significantly up-regulated in these women PMID: 19694640

Hide All

Subcellular Location

Cell membrane; Single-pass type II membrane protein.

Tissue Specificity

Predominantly expressed in NK cells (at protein level). Expressed in intraepithelial CD8-positive T cell subsets with higher frequency in gamma-delta T cells than alpha-beta T cells (at protein level). Expressed in memory gamma-delta T cells (at protein l

Database Links

HGNC: 6374

OMIM: 161555

KEGG: hsa:3821

STRING: 9606.ENSP00000352064

UniGene: Hs.512576

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA012466MB1HU
Size	US$9799
	Order now
Have Questions?	Leave a Message or Start an on-line Chat

KLRC1 (HY-0102 Biosimilar) Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background